Cell2in is rapidly and efficiently maximizing its technical capabilities
through a global collaboration network with domestic and foreign experts and medical leading companies.
Global R&D
Infrastructure
-
Cell therapeutics
development- Intractable Asthma
- Osteoarthritis (OA)
- Idiopathic pulmonary fibrosis (IPF)
- Graft-versus-host disease (GvHD)
- Multiple sclerosis (MS)
- Cell therapy for pets
-
R&D Services
- Cell quality evaluation technology
- Antioxidant and anti-aging substance screening
- Development of serum-free cell culture medium
- Development of serum-free cryoprotectant
- Mass production of customized stem cell culture medium
- Production of high-quality extracellular vesicles and exosomes
- Development of cell quality measuring device
-
Products
- Cell quality management system: FreSHcell Q / FreSHtracer kit
- Cells for therapyt & Customized cell culture medium
- Exosome
Cell2in collaborative infrastructure
Global R&D
-
Stem cell therapy
-
Autologous stem cell and immunocyte efficacy evaluation and culture medium development
T company
-
Stem cell culture and quality evaluation
O company
-
Autologous stem cell and immunocyte quality evaluation
H hospital, Japan
-
Hematopoietic stem cell quality evaluation
C company, Israel
-
Diabetes treatment clinical trial donor cell therapy quality evaluation
N company, Sweden
-
-
Exosome
-
Quality evaluation of stem cell-derived exosome of various uses
O company and S company
-
Stem cell-derived exosome mass production and separation technology development
R company, H company and R company
-
Stem cell-derived exosome for disease treatment mass production and separation technology development
E company, Lithuania
-
-
Cell production quality control system
-
Injectable cell preservative and solution development
E company, France
-
Cell mass culture quality control
L company, Switzerland
-
Cell culture supplement medium development
R company, Italy
-
Development of 3D Matrices for mass culture
R company, Poland
-
Cell-customized chemical-defined culture medium development
K company, Japan
-
Stem cell culture and quality evaluation
Korea Institute of Radiological & Medical Sciences, Asan Medical Center, and Cha Medical Center
-
Med-tech
-
Professor
Hyuk-soo Han-
Seoul National University Orthopedic Clinic
Clinical treatment of degenerative arthritis
-
-
Professor
Hye-Ryun Kang-
SNUH Department of Allergy and Clinical Immunology
Clinical treatment of refractory asthma
-
-
Professor
Sung-Soo Yoon-
SNUH Department of Hemato Oncology
Clinical treatment of GvHD and leukemia
-
-
Professor
Jong Kwan Jun-
SNUH Department of Obstetrics and Gynecology
Research of stem cells including umbilical cord stem cells
-
-
Professor
Jin-Woo Song-
Asan Medical Center Department of Pulmonology
Clinical treatment of idiopathic pulmonary fibrosis
-
-
Professor
Hee-Myung Park-
Konkuk University Veterinary Medical Teaching Hospital Veterinary Internal Medicine
Multiple sclerosis treatment research
-
-
Director
Jong-Il Kang-
Choonghyun Animal Hospital
Stem cell therapy animal disease clinical trials
-
Global Marketing
-
Ykio Takene
-
Former President of Sumitomo Bio
Entrance of Japanese cell therapy market
-
-
Summer Park
-
Development director Pharma Ventures Ltd
Transfer of European and foreign technologies
-